Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

Clinical trial NCT04957160 · COMPLETED

Trial details

NCT number: NCT04957160
Sponsor: Ipsen
Status: COMPLETED
Study type: OBSERVATIONAL

Advanced Renal Cell Carcinoma (aRCC)

Start date: 2021-09-09
Primary completion: 2022-06-15
Enrollment: 281

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.